A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
This is a continued access protocol to provide subjects who have completed Genentech, Inc.
Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1
with continued Xolair treatment. Subject eligibility will be based on disease severity and
asthma deterioration upon withdrawal of Xolair treatment. Subjects whose last Xolair dose was
<9 months prior to screening visit will continue with the same Xolair dosing regimen that
they received in the previous Genentech or Novartis clinical study.